Detailed information for compound 259593
Basic information
Technical information
Network
Hover on a compound node to display the structore
Synonyms
- phenethyl isothiocyanate
- 2257-09-2
- (2-isothiocyanatoethyl)benzene
- W401404_ALDRICH
- 4-12-00-02476 (Beilstein Handbook Reference)
- BRN 2084162
- CCRIS 3146
- EINECS 218-855-5
- NSC 87868
- Phenylaethylsenfoel [German]
- 253731_ALDRICH
- beta-Phenylethyl isothiocyanate
- ZERO/008133
- ZINC02022074
- NCI60_041942
- .beta.-Phenethyl isothiocyanate
- .beta.-Phenylethyl isothiocyanate
- 2-Phenylethyl isothiocyanate
- Benzene, (2-isothiocyanatoethyl)-
- Isothiocyanic acid, phenethyl ester
- NSC87868
- Phenethyl mustard oil
- Phenylaethylsenfoel
- Phenylethyl isothiocyanate
- Phenylethyl mustard oil
- WLN: SCN2R
- 77972_FLUKA
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | endothelial PAS domain protein 1 | References | |
| Homo sapiens | transient receptor potential cation channel, subfamily A, member 1 | Starlite/ChEMBL | References |
| Homo sapiens | macrophage migration inhibitory factor (glycosylation-inhibiting factor) | Starlite/ChEMBL | References |
| Homo sapiens | hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | References | |
| Homo sapiens | cytochrome P450, family 2, subfamily A, polypeptide 6 | Starlite/ChEMBL | References |
| Homo sapiens | cytochrome P450, family 2, subfamily A, polypeptide 13 | Starlite/ChEMBL | References |
| Homo sapiens | cytochrome P450, family 2, subfamily E, polypeptide 1 | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Brugia malayi | cytochrome P450 | cytochrome P450, family 2, subfamily A, polypeptide 6 | 494 aa | 485 aa | 32.8 % |
| Brugia malayi | cytochrome P450 | cytochrome P450, family 2, subfamily A, polypeptide 13 | 494 aa | 488 aa | 33.6 % |
| Trypanosoma brucei | cytochrome P450, putative | cytochrome P450, family 2, subfamily E, polypeptide 1 | 493 aa | 494 aa | 21.1 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Trichomonas vaginalis | aldo/keto reductase, putative | 0.0766 | 1 | 1 |
| Toxoplasma gondii | aldo/keto reductase family oxidoreductase | 0.0222 | 0.1983 | 0.0307 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
| Plasmodium vivax | aldehyde reductase, putative | 0.0222 | 0.1983 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Loa Loa (eye worm) | hypoxia-induced factor 1 | 0.0364 | 0.4069 | 0.4069 |
| Onchocerca volvulus | 0.0766 | 1 | 1 | |
| Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase | 0.0766 | 1 | 1 |
| Toxoplasma gondii | oxidoreductase, aldo/keto reductase family protein | 0.0222 | 0.1983 | 0.0307 |
| Brugia malayi | hypoxia-induced factor 1 | 0.0364 | 0.4069 | 0.3793 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Brugia malayi | Bm-MIF-1, identical | 0.0205 | 0.1729 | 0.1345 |
| Onchocerca volvulus | 0.0766 | 1 | 1 | |
| Trypanosoma cruzi | aldo-keto reductase | 0.0766 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0394 | 0.4518 | 0.4518 |
| Entamoeba histolytica | alcohol dehydrogenase, putative | 0.0222 | 0.1983 | 0.0307 |
| Leishmania major | aldo-keto reductase-like protein | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0766 | 1 | 1 |
| Schistosoma mansoni | potassium channel beta | 0.0222 | 0.1983 | 0.161 |
| Echinococcus multilocularis | aldo keto reductase | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0222 | 0.1983 | 0.0307 |
| Entamoeba histolytica | aldose reductase, putative | 0.0766 | 1 | 1 |
| Trypanosoma brucei | prostaglandin f synthase | 0.0766 | 1 | 1 |
| Echinococcus granulosus | voltage gated potassium channel subunit | 0.0222 | 0.1983 | 0.0523 |
| Echinococcus multilocularis | aldehyde reductase | 0.0544 | 0.6731 | 0.6136 |
| Trypanosoma cruzi | aldo/keto reductase, putative | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Entamoeba histolytica | aldose reductase, putative | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0222 | 0.1983 | 0.0307 |
| Mycobacterium ulcerans | oxidoreductase | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Loa Loa (eye worm) | oxidoreductase | 0.0766 | 1 | 1 |
| Loa Loa (eye worm) | oxidoreductase | 0.0766 | 1 | 1 |
| Loa Loa (eye worm) | oxidoreductase | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Leishmania major | prostaglandin f2-alpha synthase/D-arabinose dehydrogenase | 0.0766 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0766 | 1 | 1 |
| Plasmodium falciparum | aldehyde reductase, putative | 0.0222 | 0.1983 | 1 |
| Trichomonas vaginalis | alcohol dehydrogenase, putative | 0.0222 | 0.1983 | 0.0307 |
| Mycobacterium tuberculosis | Probable oxidoreductase | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo/keto reductase, putative | 0.0766 | 1 | 1 |
| Brugia malayi | glutamate-cysteine ligase modifier subunit | 0.0222 | 0.1983 | 0.161 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Brugia malayi | hypothetical protein | 0.0394 | 0.4518 | 0.4264 |
| Loa Loa (eye worm) | oxidoreductase | 0.0766 | 1 | 1 |
| Entamoeba histolytica | alcohol dehydrogenase, putative | 0.0222 | 0.1983 | 0.0307 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
| Brugia malayi | NADH-dependent xylose reductase | 0.0222 | 0.1983 | 0.161 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0222 | 0.1983 | 0.0307 |
| Onchocerca volvulus | 0.0766 | 1 | 1 | |
| Schistosoma mansoni | aldo-keto reductase | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Entamoeba histolytica | aldose reductase, putative | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo/keto reductase, putative | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0222 | 0.1983 | 0.0307 |
| Schistosoma mansoni | aldo-keto reductase | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | dihydrodiol dehydrogenase, putative | 0.0766 | 1 | 1 |
| Schistosoma mansoni | transient receptor potential cation channel subfamily A member | 0.0192 | 0.1541 | 0.1148 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Plasmodium falciparum | aldo-keto reductase, putative | 0.0222 | 0.1983 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Plasmodium vivax | oxidoreductase, aldo/keto reductase domain containing protein | 0.0222 | 0.1983 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Loa Loa (eye worm) | macrophage migration inhibitory factor | 0.0205 | 0.1729 | 0.1729 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Giardia lamblia | Aldose reductase | 0.0766 | 1 | 1 |
| Echinococcus granulosus | hypothetical protein | 0.0766 | 1 | 1 |
| Onchocerca volvulus | 0.0766 | 1 | 1 | |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
| Leishmania major | aldehyde reductase, putative,oxidoreductase, putative | 0.0766 | 1 | 1 |
| Giardia lamblia | Aldose reductase | 0.0766 | 1 | 1 |
| Mycobacterium leprae | PROBABLE OXIDOREDUCTASE | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase | 0.0766 | 1 | 1 |
| Mycobacterium leprae | Conserved hypothetical protein | 0.0544 | 0.6731 | 0.5922 |
| Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase family 1, member B4 | 0.0766 | 1 | 1 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | transient receptor potential cation channel | 0.0196 | 0.1598 | 0.0068 |
| Echinococcus multilocularis | voltage gated potassium channel subunit | 0.0222 | 0.1983 | 0.0523 |
| Loa Loa (eye worm) | glutamate-cysteine ligase modifier subunit | 0.0222 | 0.1983 | 0.1983 |
| Echinococcus multilocularis | aldo keto reductase | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
| Echinococcus multilocularis | aldo keto reductase | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase family 1, member B4 | 0.0222 | 0.1983 | 0.0523 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Loa Loa (eye worm) | oxidoreductase | 0.0766 | 1 | 1 |
| Onchocerca volvulus | 0.0766 | 1 | 1 | |
| Echinococcus granulosus | aldehyde reductase | 0.0544 | 0.6731 | 0.6136 |
| Trypanosoma brucei | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Brugia malayi | oxidoreductase, aldo/keto reductase family protein | 0.0766 | 1 | 1 |
| Leishmania major | aldo/keto reductase, putative,aldo/keto reductase family-like protein | 0.0222 | 0.1983 | 0.0307 |
| Toxoplasma gondii | aldose reductase, putative | 0.0766 | 1 | 1 |
| Echinococcus granulosus | transient receptor potential cation channel | 0.0196 | 0.1598 | 0.0068 |
| Onchocerca volvulus | 0.0766 | 1 | 1 | |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Leishmania major | prostaglandin f synthase, putative | 0.0766 | 1 | 1 |
| Schistosoma mansoni | pol-related | 0.0766 | 1 | 1 |
| Toxoplasma gondii | aldo-keto reductase | 0.0222 | 0.1983 | 0.0307 |
| Trichomonas vaginalis | aldo-keto reductase, putative | 0.0766 | 1 | 1 |
| Echinococcus granulosus | aldo keto reductase family 1 member B4 | 0.0766 | 1 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (binding) | Induction of ERK1/2 phosphorylation at threonine 202/tyrosine 204 in human MCF7 cells after 3 hrs by immunoblotting analysis | ChEMBL. | 22607231 | |
| Activity (functional) | TP_TRANSPORTER: cell accumulation of 0.05u daunomycin in MCF-7/ADR cells | ChEMBL. | 15176077 | |
| Activity (binding) | Induction of p53 activation in human MCF7 cells at 20 uM incubated for 24 hrs by immunoblot analysis | ChEMBL. | 21241062 | |
| Activity (binding) | Agonist activity at mouse TRPM8 expressed in TREx-HEK cells at 300 uM by Fluo-4 AM dye-based Ca2+ imaging assay | ChEMBL. | 26263397 | |
| Activity (binding) | Induction of p53 depletion in human A549 cells at 20 uM incubated for 2 to 24 hrs by immunoblot analysis | ChEMBL. | 21241062 | |
| Activity (binding) | Induction of p53 depletion in human MCF10A cells at 15 uM incubated for 2 to 24 hrs by immunoblot analysis | ChEMBL. | 21241062 | |
| Activity (binding) | Induction of p53 depletion in human HCT116 cells at 20 uM incubated for 2 to 24 hrs by immunoblot analysis | ChEMBL. | 21241062 | |
| Activity (binding) | Induction of p53 depletion in human MCF7 cells at 20 uM incubated for 2 to 24 hrs by immunoblot analysis | ChEMBL. | 21241062 | |
| Activity (ADMET) | Toxicity in human UACC-903 cells xenografted in Harlan Sprague-Dawley athymic nude mouse assessed as effect on body weight at 2.5 uM, ip administered three times per week | ChEMBL. | 19053750 | |
| Activity (functional) | = 4.5 % | Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM after 72 hrs using propidium iodide staining by flow cytometry (Rvb = 16 +/- 2.1 %) | ChEMBL. | 21704523 |
| Activity (functional) | = 7.5 % | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM after 72 hrs using propidium iodide staining by flow cytometry (Rvb = 12.5 +/- 1.7 %) | ChEMBL. | 21704523 |
| Activity (functional) | = 8 % | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 13.5 +/- 0.7 %) | ChEMBL. | 21704523 |
| Activity (functional) | = 10.5 % | Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 17 +/- 0.3 %) | ChEMBL. | 21704523 |
| Activity (functional) | = 11 % | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 14.5 +/- 1.2 %) | ChEMBL. | 21704523 |
| Activity (functional) | = 14.5 % | Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 10 uM after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 18 +/- 1.5%) | ChEMBL. | 21704523 |
| Activity (functional) | = 22.5 % | Cell cycle arrest in human A549 cells assessed as accumulation at sub G0/G1 phase at 10 uM after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 4.5 +/- 1.4 %) | ChEMBL. | 21704523 |
| Activity (ADMET) | = 26 % | Inactivation of human CYP2E1 expressed in Escherichia coli MV1304 assessed as remaining enzyme activity at 25 uM in presence of 1.2 mM NADPH after dialysis in presence of fresh reductase by 7-EFC O-de-ethylation activity detection based spectrofluorometry | ChEMBL. | 23371965 |
| Activity (ADMET) | = 27 % | Inactivation of human CYP2E1 expressed in Escherichia coli MV1304 assessed as remaining enzyme activity at 25 uM in presence of 1.2 mM NADPH after dialysis by 7-EFC O-de-ethylation activity detection based spectrofluorometry | ChEMBL. | 23371965 |
| Activity (functional) | = 29 % | Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 10 uM after 72 hrs using propidium iodide staining by flow cytometry (Rvb = 62 +/- 3.3 %) | ChEMBL. | 21704523 |
| Activity (functional) | = 39 % | Cell cycle arrest in human A549 cells assessed as accumulation at sug G0/G1 phase at 10 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 6.5 +/- 1.4 %) | ChEMBL. | 21704523 |
| Activity (functional) | = 40 % | Antitumor activity in human UACC-903 cells xenografted in Harlan Sprague-Dawley athymic nude mouse assessed as reduction in tumor size at 2.5 uM, ip administered three times per week | ChEMBL. | 19053750 |
| Activity (functional) | = 40.5 % | Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 62 +/- 1.2 %) | ChEMBL. | 21704523 |
| Activity (ADMET) | = 42 % | Inactivation of human CYP2E1 expressed in Escherichia coli MV1304 assessed as remaining P450 level at 25 uM in presence of 1.2 mM NADPH after dialysis by CO difference spectral method | ChEMBL. | 23371965 |
| Activity (functional) | = 51 % | Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 62 +/- 2.4 %) | ChEMBL. | 21704523 |
| Activity (functional) | = 54 % | Cell cycle arrest in human A549 cells assessed as accumulation at sub G0/G1 phase at 10 uM after 72 hrs using propidium iodide staining by flow cytometry (Rvb = 7.5 +/- 1.3 %) | ChEMBL. | 21704523 |
| Activity (ADMET) | = 64 % | Inactivation of human CYP2E1 expressed in Escherichia coli MV1304 assessed as remaining heme level at 25 uM in presence of 1.2 mM NADPH after dialysis by HPLC method | ChEMBL. | 23371965 |
| Activity (functional) | = 75 % | Reduction in glutathione levels in human A549 cells at 10 uM after 30 mins by Ellmans assay relative to control | ChEMBL. | 21704523 |
| Activity (ADMET) | = 82 % | Inactivation of human CYP2E1 expressed in Escherichia coli MV1304 assessed as remaining enzyme activity at 25 uM after dialysis by 7-EFC O-de-ethylation activity detection based spectrofluorometry | ChEMBL. | 23371965 |
| Activity (ADMET) | = 85 % | Inactivation of human CYP2E1 expressed in Escherichia coli MV1304 assessed as remaining enzyme activity at 25 uM after dialysis in presence of fresh reductase by 7-EFC O-de-ethylation activity detection based spectrofluorometry | ChEMBL. | 23371965 |
| Activity (ADMET) | = 93 % | Inactivation of human CYP2E1 expressed in Escherichia coli MV1304 assessed as remaining P450 level at 25 uM after dialysis by CO difference spectral method | ChEMBL. | 23371965 |
| Activity (binding) | = 94 % | Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control | ChEMBL. | 18457386 |
| Activity (ADMET) | = 100 % | Inactivation of human CYP2E1 expressed in Escherichia coli MV1304 assessed as remaining heme level at 25 uM after dialysis by HPLC method | ChEMBL. | 23371965 |
| Activity (functional) | = 2 fold | TP_TRANSPORTER: increase in Daunomycin intracellular accumulation (Daunomycin: 0.05 uM, Phenylhexyl isothiocyanate: 100 uM) in PANC-1 cells | ChEMBL. | 12425469 |
| EC50 (binding) | = 0.37 uM | Activation of human TRPA1 expressed in TREx-HEK cells by Fluo-4 AM dye-based Ca2+ imaging assay | ChEMBL. | 26263397 |
| EC50 (binding) | = 10 uM | Activation of TRPA1 channel | ChEMBL. | 20356305 |
| EC50 (binding) | = 180 uM | Activation of human TRPV1 expressed in TREx-HEK cells by Fluo-4 AM dye-based Ca2+ imaging assay | ChEMBL. | 26263397 |
| GC50 (functional) | = 0.84 uM | Median growth inhibitory concentration of compound tested invitro against human leukemia 60 cells | ChEMBL. | 10636242 |
| GI50 (functional) | -6.683 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
| GI50 (functional) | -6.496 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
| GI50 (functional) | -6.488 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
| GI50 (functional) | -6.415 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
| GI50 (functional) | -6.344 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
| GI50 (functional) | -5.807 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
| GI50 (functional) | -5.799 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
| IC50 (binding) | = 1.6 uM | Inhibition of macrophage migration inhibitory factor tautomerase activity in human Jurkat T cells using L-dopachrome methyl ester as substrate incubated for 30 mins prior to substrate addition measured for 2 mins by spectrophotometric analysis | ChEMBL. | 25743213 |
| IC50 (binding) | = 7.5 uM | Inhibition of Serine/threonine-protein kinase mTOR complex 1-mediated HIF1alpha RNA translation in human MCF7 cells pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis | ChEMBL. | 22607231 |
| IC50 (functional) | = 8 uM | Inhibition of growth in TSC2-deficient MEF cells after 6 days | ChEMBL. | 22607231 |
| IC50 (functional) | = 9.7 uM | Antiproliferative activity against human T47D cells after 72 hrs by SRB assay | ChEMBL. | 21704523 |
| IC50 (functional) | = 9.8 uM | Antiproliferative activity against doxorubicin-resistant human LoVo cells after 72 hrs by SRB assay | ChEMBL. | 21704523 |
| IC50 (functional) | = 12 uM | Cytotoxicity against human UACC-903 cells after 72 hrs by MTS assay | ChEMBL. | 19053750 |
| IC50 (functional) | = 13.5 uM | Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay | ChEMBL. | 21704523 |
| IC50 (functional) | = 13.5 uM | Antiproliferative activity against human LoVo cells assessed as reduction in cell viability after 72 hrs by SRB assay | ChEMBL. | 26639764 |
| IC50 (functional) | = 14 uM | Cytotoxicity against human Caco-2 cells after 72 hrs by MTS assay | ChEMBL. | 19053750 |
| IC50 (functional) | = 15 uM | Cytotoxicity against human HT1080 cells after 72 hrs by MTS assay | ChEMBL. | 19053750 |
| IC50 (binding) | = 16 uM | Inhibition of human recombinant macrophage migration inhibitory factor tautomerase activity expressed in Escherichia coli DH5alpha using L-dopachrome methyl ester as substrate incubated for 5 mins prior to substrate addition measured for 2 mins by spectrophotometric analysis | ChEMBL. | 25743213 |
| IC50 (functional) | = 16.3 uM | Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay | ChEMBL. | 21704523 |
| IC50 (functional) | = 16.8 uM | Antiproliferative activity against human A549 cells after 72 hrs by SRB assay | ChEMBL. | 21704523 |
| IC50 (functional) | = 23.2 uM | Antiproliferative activity against human OVCAR-3 cells | ChEMBL. | 18855447 |
| IC50 (functional) | = 24 uM | Cytotoxicity against human PC-3 cells after 72 hrs by MTS assay | ChEMBL. | 19053750 |
| IC50 (functional) | = 38 uM | Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTS assay | ChEMBL. | 19053750 |
| IC50 (functional) | > 100 uM | Cytotoxicity against human T98G cells after 72 hrs by MTS assay | ChEMBL. | 19053750 |
| Inhibition (binding) | Inhibition of mTORC1 in human MCF7 cells assessed as reduction of p70S6K phosphorylation at 20 uM after 15 mins by immunoblotting analysis | ChEMBL. | 22607231 | |
| Inhibition (binding) | Inhibition of mTORC1 in human MCF7 cells assessed as reduction of p70S6K phosphorylation at threonine 389 after 3 hrs by immunoblotting analysis | ChEMBL. | 22607231 | |
| Inhibition (binding) | Inhibition of Serine/threonine-protein kinase mTOR complex 1-mediated HIF1alpha RNA translation in human MCF7 cells at 20 uM pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis | ChEMBL. | 22607231 | |
| Inhibition (binding) | Inhibition of mTORC1 in human MCF7 cells assessed as reduction of 4E-BP1 phosphorylation after 3 hrs by immunoblotting analysis | ChEMBL. | 22607231 | |
| Inhibition (ADMET) | = -32 % | Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting | ChEMBL. | 22541068 |
| Inhibition (ADMET) | = -16.4 % | Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting | ChEMBL. | 22541068 |
| Inhibition (ADMET) | = 12.3 % | Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting | ChEMBL. | 22541068 |
| Kd (ADMET) | = 0.43 uM | Binding affinity to CYP2A13 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm | ChEMBL. | 22696418 |
| Kd (ADMET) | = 6.2 uM | Binding affinity to CYP2A6 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm | ChEMBL. | 22696418 |
| Ki (ADMET) | = 1.7 uM | Mixed inhibition of CYP2A6 (unknown origin) | ChEMBL. | 22696418 |
| Ki (ADMET) | = 3.8 uM | Mixed inhibition of CYP2A13 (unknown origin) | ChEMBL. | 22696418 |
| Ki (ADMET) | = 9.98 uM | Mechanism based inhibition of human cytochrome P450 2E1 | ChEMBL. | 16248836 |
| Ki (ADMET) | = 11 uM | Inhibition of human CYP2E1 expressed in Escherichia coli MV1304 assessed as reduction in 7-EFC O-de-ethylation activity by spectrofluorometry based double reciprocal plot | ChEMBL. | 23371965 |
| Kinact (ADMET) | = 0.23 /min | Inhibition of human CYP2E1 expressed in Escherichia coli MV1304 assessed as reduction in 7-EFC O-de-ethylation activity by spectrofluorometry based double reciprocal plot | ChEMBL. | 23371965 |
| Kinact (ADMET) | = 0.339 min-1 | Mechanism based inhibition of human cytochrome P450 2E1 | ChEMBL. | 16248836 |
| max activation (binding) | = 43 % | Activation of human TRPV1 expressed in TREx-HEK cells by Fluo-4 AM dye-based Ca2+ imaging assay relative to 10 uM capsaicin | ChEMBL. | 26263397 |
| max activation (binding) | = 94 % | Activation of human TRPA1 expressed in TREx-HEK cells by Fluo-4 AM dye-based Ca2+ imaging assay relative to 100 uM ITC | ChEMBL. | 26263397 |
| mechanism based inhibition (ADMET) | Mechanism based inhibition of rat cytochrome P450 CYP2B1 measured by 7-EFC O-deethylation activity | ChEMBL. | 16248836 | |
| Potency (functional) | 21.9206 uM | PubChem BioAssay: Tox21. qHTS assay for small molecule activators of the heat shock response signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 43.7373 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the AP-1 signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 55.062 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 55.062 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the NFkB signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 77.1154 uM | PubChem BioAssay: Tox21. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
| T1/2 (ADMET) | = 3 min | Inhibition of human CYP2E1 expressed in Escherichia coli MV1304 assessed as half life for enzyme inactivation by measuring reduction in 7-EFC O-de-ethylation activity by spectrofluorometry based double reciprocal plot | ChEMBL. | 23371965 |
| TC50 (functional) | = 1.37 uM | Median toxic concentration of compound tested invitro against human leukemia 60 cells | ChEMBL. | 10636242 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Mus musculus | ChEMBL23 | 22607231 | |
| Homo sapiens | ChEMBL23 | 19053750 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- Search by CAS
- Search by CAS
- ChEMBL: CHEMBL151649
- PubChem: 16741
Bibliographic References
13 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.